Brief: Cantargia Announces CAN10 Results
11/11/2024 06:35
Nov 11 (Reuters) - Cantargia AB CANTA.ST :
* CAN10, SIMULTANEOUSLY TARGETING IL-1, IL-33 AND IL-36,
GENERATED
MUCH STRONGER EFFECTS THAN TREATMENT BLOCKING ONLY IL-1. CAN10
IS IN PHASE 1 CLINICAL DEVELOPMENT
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML